Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

  • C.W. Hong National Institutes of Health Clinical Center, Cleveland Clinic
  • S.K. Libutti Albert Einstein College of Medicine, National Institutes of Health
  • B.J. Wood National Institutes of Health Clinical Center, National Institutes of Health
Keywords: RFA, ablation, hepatocellular carcinoma, doxorubicin, liposomes

Abstract

Radiofrequency ablation (rfa) is a standard treatment for small, unresectable hepatocellular carcinomas (hccs). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

Author Biographies

C.W. Hong, National Institutes of Health Clinical Center, Cleveland Clinic
Center for Interventional Oncology, Radiology and Imaging Sciences, Lerner College of Medicine
S.K. Libutti, Albert Einstein College of Medicine, National Institutes of Health
Montefioreā€“Einstein Center for Cancer Care, Department of Surgery, National Cancer Institute
B.J. Wood, National Institutes of Health Clinical Center, National Institutes of Health
Center for Interventional Oncology, Radiology and Imaging Sciences, National Cancer Institute
How to Cite
Hong, C., Libutti, S., & Wood, B. (1). Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma. Current Oncology, 20(3), e274-e277. https://doi.org/10.3747/co.20.1266
Section
Case Report